Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146676 · ClinicalTrials.gov registry record
The Ohio State University Dermatology Biorepository
A clinical trial of Hidradenitis Suppurativa, sponsored by Ohio State University.
- Recruiting
- Registry status
- 175
- Enrollment target
- 1
- Study location
NCT03146676: Recruiting study of Hidradenitis Suppurativa, sponsored by Ohio State University.
NCT03146676 is a study of Hidradenitis Suppurativa that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 175 participants, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03146676, a study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- 175 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
Conditions Studied
Study Locations (1)
Ohio
- OSU Dermatology West - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2030-12-31 |
What NCT03146676 shows while recruiting
NCT03146676 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 0 interventions.
NCT03146676 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03146676 about?
NCT03146676 is a clinical study titled "The Ohio State University Dermatology Biorepository". This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
What is the current status of trial NCT03146676?
This trial is currently recruiting. The enrollment target is 175 participants. The study started on 2017-04-19. Estimated completion is 2030-12-31.
What conditions does trial NCT03146676 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
Who is sponsoring clinical trial NCT03146676?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03146676 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03146676's enrollment target sits among peer trials
175 25th of 52 higher than 28 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI